AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Esophageal Cancer Drugs Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Company and Eli Lilly and Company | Technavio

February 25, 2020 GMT
Global Esophageal Cancer Drugs Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Company and Eli Lilly and Company | Technavio
Global Esophageal Cancer Drugs Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Company and Eli Lilly and Company | Technavio

LONDON--(BUSINESS WIRE)--Feb 25, 2020--

Technavio has been monitoring the global esophageal cancer drugs market since 2018 and the market is poised to grow by USD 1.5 billion during 2019-2023, progressing at a CAGR of more than 8% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200225005443/en/

Technavio has announced its latest market research report titled Global Esophageal Cancer Drugs Market 2019-2023 (Graphic: Business Wire)

Read the 118-page report with TOC on “Esophageal Cancer Drugs Market Analysis Report by Product (Targeted therapy and Chemotherapy), Type (Adenocarcinoma and Squamous cell carcinoma), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023”.

https://www.technavio.com/report/global-esophageal-cancer-drugs-market-industry-analysis

The market is driven by the presence of favorable reimbursement scenario for esophageal cancer. In addition, the use of multimodality treatment approach is anticipated to boost the growth of the esophageal cancer drugs market.

Reimbursement policies for esophageal cancer drugs are generally favorable in developed countries. For instance, Medicare, a federal government program for healthcare in the US covers chemotherapy for patients with esophageal cancer under its Medicare Part A and Medicare Part B programs. Similarly, the Health Insurance Review and Assessment Service of South Korea approved reimbursement for the esophageal cancer drug, CYRAMZA in 2018. The presence of such favorable reimbursement programs is expected to drive the growth of the global esophageal cancer drugs market during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing

Major Five Esophageal Cancer Drugs Market Companies:

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates its business through the Biopharmaceuticals segment. ETOPOPHOS and TAXOL are the key offerings of the company. These drugs are indicated for the treatment of esophageal cancer.

Eli Lilly and Company

Eli Lilly and Company operates its business through segments such as Human pharmaceutical products and Animal health products. CYRAMZA is the key offering of the company.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd operates its business through segments such as Pharmaceuticals and Diagnostics. Herceptin is the key offering of the company.

Merck & Co., Inc.

Merck & Co., Inc. operates its business through segments such as Pharmaceutical, Animal Health, Healthcare Services, and Alliances. KEYTRUDA is the key offering of the company.

Sanofi

Sanofi operates its business through segments such as Pharmaceuticals, Vaccines, and Consumer Healthcare. TAXOTERE is the key offering of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform

Technavio has segmented the esophageal cancer drugs market based on the product, type, and region.

Esophageal Cancer Drugs Product Outlook (Revenue, USD Billion, 2019 - 2023)

  • Targeted therapy
  • Chemotherapy

Esophageal Cancer Drugs Type Outlook (Revenue, USD Billion, 2019 - 2023)

  • Adenocarcinoma
  • Squamous cell carcinoma

Esophageal Cancer Drugs Regional Outlook (Revenue, USD Billion, 2019 - 2023)

  • Asia
  • Europe
  • North America
  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report

Related Reports on Healthcare are:

Global Bone Cancer Drugs Market – Global bone cancer drugs market by indication (osteosarcoma, Ewing’s sarcoma, chondrosarcoma, and others) and geography (Asia, Europe, North America, and ROW).

Global Oral Cancer Therapeutics Market – Global oral cancer therapeutics market by product (targeted therapy and chemotherapy) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20200225005443/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Technavio Research

Copyright Business Wire 2020.

PUB: 02/25/2020 08:00 AM/DISC: 02/25/2020 08:01 AM

http://www.businesswire.com/news/home/20200225005443/en